Page 1 | Search Results | ASH Clinical News | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

News

Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

Katie Robinson

Abstract

View News titled, Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

News

Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

Katie Robinson

Abstract

View News titled, Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

News

EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

Katie Robinson

Abstract

View News titled, EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

News

IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

Katie Robinson

Abstract

View News titled, IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

News

Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

Katie Robinson

Abstract

View News titled, Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

News

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

Katie Robinson

Abstract

View News titled, Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

News

Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

Katie Robinson

Abstract

View News titled, Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

News

Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

Katie Robinson

Abstract

View News titled, Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

News

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Katie Robinson

Abstract

View News titled, Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

News

Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

Katie Robinson

Abstract

View News titled, Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

News

Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

Katie Robinson

Abstract

View News titled, Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

News

Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

Katie Robinson

Abstract

View News titled, Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

News

Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

Katie Robinson

Abstract

View News titled, Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

News

Pneumococcal Meningitis Mortality Remains High in Children in France With SCD

Katie Robinson

Abstract

View News titled, Pneumococcal Meningitis Mortality Remains High in Children in France With SCD

News

Low Rates of High-Grade Toxicities Seen With Fresh CAR T-Cell Therapy in R/R NHL

Katie Robinson

Abstract

View News titled, Low Rates of High-Grade Toxicities Seen With Fresh CAR T-Cell Therapy in R/R NHL

News

Circulating Tumor DNA Analysis Identifies Classical Hodgkin Lymphoma Genotypes

Katie Robinson

Abstract

View News titled, Circulating Tumor DNA Analysis Identifies Classical Hodgkin Lymphoma Genotypes

News

Daratumumab Shows Clinical Activity, No New Safety Concerns With Extended Use in Intermediate/High-Risk Smoldering MM

Katie Robinson

Abstract

View News titled, Daratumumab Shows Clinical Activity, No New Safety Concerns With Extended Use in Intermediate/High-Risk Smoldering MM

News

Cilta-Cel Shows Superior Efficacy, Survival Over Ide-Cel, but Higher Toxicity in R/R MM

Katie Robinson

Abstract

View News titled, Cilta-Cel Shows Superior Efficacy, Survival Over Ide-Cel, but Higher Toxicity in R/R MM

News

Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

Katie Robinson

Abstract

View News titled, Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

News

Clonal Hematopoiesis Linked to Increased Risk for Heart Failure, Non-Relapse Mortality After AHCT for Lymphoma

Katie Robinson

Abstract

View News titled, Clonal Hematopoiesis Linked to Increased Risk for Heart Failure, Non-Relapse Mortality After AHCT for Lymphoma

Update search

NARROW

Publications

Format

Topics

Date

Availability

Erythroid-Predominant MDS Shows Specific Genetic Features, Poor Outcomes With Venetoclax

Phase I R/R MM Study of Talquetamab Plus Daratumumab Achieves Safety Endpoint, Durable Responses

EMD Linked to Severe Toxicities After CAR T-Cell Therapy in MM

IMS-IMWG Releases New Consensus Definition of High-Risk MM Based on Genomics

Single-Run NGS Approach for MDS Improves Diagnostic Accuracy, Workflow in Resource-Constrained Setting

Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A

Long-Term Data Confirm Early Rituximab Monotherapy Delays New Treatment in Advanced, Asymptomatic LTBFL

Immunoglobulin Replacement Therapy in MM May Reduce Risk, Severity of Infections, Development of Hypogammaglobulinemia

Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors

Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints

Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP

Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD

Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study

Pneumococcal Meningitis Mortality Remains High in Children in France With SCD

Low Rates of High-Grade Toxicities Seen With Fresh CAR T-Cell Therapy in R/R NHL

Circulating Tumor DNA Analysis Identifies Classical Hodgkin Lymphoma Genotypes

Daratumumab Shows Clinical Activity, No New Safety Concerns With Extended Use in Intermediate/High-Risk Smoldering MM

Cilta-Cel Shows Superior Efficacy, Survival Over Ide-Cel, but Higher Toxicity in R/R MM

Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM

Clonal Hematopoiesis Linked to Increased Risk for Heart Failure, Non-Relapse Mortality After AHCT for Lymphoma

ASH Publications

American Society of Hematology

Update search

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only